• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Harvard researchers stumble on stem cell clue

Harvard researchers stumble on stem cell clue

November 7, 2010 By MassDevice staff

Stem cells graphic

An interdisciplinary group of Harvard scientists stumbled across a new mechanism involved in the reprogramming of stem cells that could help "fine tune" induced pluripotent stem cells into specific cell types.

The researchers, variously affiliated with the Harvard Stem Cell Institute, the Broad Institute of Harvard and MIT, Harvard’s Department of Stem Cell and Regenerative Biology, Children’s Hospital Boston and Beth Israel Deaconess Medical Center, identified a set of genetic elements called lincRNAs.

"This is the first time that this new type of gene has been implicated in the reprogramming process," co-author John Rinn said in prepared remarks "This finding gives us another set of fingers to play on the genomic piano that controls the ‘music’ of cellular reprogramming."

"We know reprogramming resets the genome [of the reprogrammed cell] globally," added co-author George Daley of HSCI and Children’s Hospital. “What we’ve learned by working with John is that lincRNAs play essential roles in the reprogramming process. We’ve even identified one lincRNA that enhances reprogramming, which is tantalizing evidence that we can make reprogramming more efficient by harnessing lincRNAs. Our groups came together to answer a question that neither group could answer alone."

In September, another team of Harvard researchers announced the discovery of a way to reprogram human skin cells so that they become stem cells, bypassing the creation of stem cell lines from human embryos. The latest discovery, published online by Nature Genetics, could hold a clue about why that method works and could also be used to refine that technique.

"We started out looking for something else: We wanted to know what happens when you program skin cells that originate in different parts of the body into stem cells," Rinn said. "George and I were on a committee meeting together with a student who didn’t know the anatomic origin of the skin cells used to make stem cells. A light bulb went off that it may be interesting to make stem cells from skin cells originating all around the body and see if they ‘remember’ where they came from. Sabine Loewer, the lead author on the paper, immediately jumped at the idea as well — which was very brave for such a risky project.

"It turned out they didn’t matter where the cells came from, which is in itself an important finding. But in the process we found that hundreds of lincRNA genes were turned on and off during the reprogramming, so we focused on the ones that turned on, to see if they were part of the pluripotency process, and they were," Rinn said.

Filed Under: Uncategorized

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy